Omega-3s vs Pure EPA in Clinical Practice

Rationale for the Use of Fish Oil

Primary and Secondary CVD Prevention Trials Evaluating Treatment of TGs

Rationale for the Use of Highly Purified EPA

REDUCE-IT Study Design

REDUCE-IT Primary and Secondary Endpoint Results

REDUCE-IT Prespecified Hierarchical Testing

REDUCE-IT CV Benefit of EPA Independent of LDL-C Levels

Ischemic Event Reduction With Icosapent Ethyl

Ischemic Event Reduction With Icosapent Ethyl Statistical Handling

REDUCE-IT Analysis Reduction of First and Subsequent Events

First and Total Events Over the Years

Primary Composite Endpoint Total Endpoint Events by Baseline TG Tertiles

REDUCE-IT Change in Biomarkers After 1 Year

Risk Differences With Icosapent Ethyl

Safety Results

REDUCE-IT Serious Bleeding

Medications Taken at Baseline

Membrane Stabilization

Effects of EPA on Plaque Progression

Prescription-Only Omega-3s vs Dietary Supplement Omega-3s

2018 Cholesterol Guidelines Secondary Prevention in Patients With Clinical ASCVD

Collaborative Care

Conclusion

Abbreviations

Abbreviations (cont)

Abbreviations (cont)